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Summary, discussion and future perspectives
Summary
Despite the introduction of relatively new antineoplastic drugs such as paclitaxel and
topotecan in the treatment of advanced ovarian carcinoma, there remains a high percentage of
patients who cannot be cured. Intrinsic or acquired resistance to currently available cytotoxic
agents is the major obstacle in the treatment of patients with advanced ovarian carcinoma.
Increasing the drug dose by e.g. intraperitoneal treatment has a limited additional effect.
Therefore, more insight into the cellular mechanisms responsible for both drug response and
drug resistance should help to develop more effective treatment methods.
In this thesis several studies in ovarian cancer are described. which focus on factors related to
drug response and prognosis.
Chapter I reviews the available data on clinicopathologic prognostic factors in ovarian
cancer and on cell biologrcal parameters involved in drug resistance and apoptosis. Currently,
the only factors which influence treatment decisions are the classic prognostic factors. The
most important prognostic factor is FIGO stage of disease at diagnosis. Additional prognostic
value can be attributed to the presence of residual tumor after first laparotomy, clinical
performance status, age and tumor differentiation grade. However, these factors are poor
predictors of the tumor response to chemotherapy. In vitro studies have identified numerous
factors which determine the chemosensitivity of tumor cells. "Classic" concepts of resistance
to cytotoxic drugs are related to the inability of drugs to reach the intracellular target,
enhanced efflux of drugs, increased detoxification of active drugs, enhanced DNA repair or
increased tolerance to DNA crosslinks. Especially multidrug resistance (conferred by amongst
others, the membrane transporter proteins P-gp and MRPI) hàs extensively been studied. /r
vitro, there is a strong relation between these proteins and the emergence of drug resistance.
Sofar, however, it has been difficult to translate these in vitro data into clinical practice.
Furthermore, strategies aimed at reversal of these resistance mechanisms did not yet result in
a treatment advantage for patients with solid tumors.
It is becoming increasingly apparent that conventional cytotoxic drugs exert their effect by the
cellular machinery that controls the cell cycle and the molecular pathways that mediate
programmed cell death or apoptosis.' Suppression of drug-induced apoptosis is considered to
be a general mechanism for drug resistance of tumor cells. The p53 tumor suppressor protein
plays a key role in coordinating this process. Mutations in the p53 gene occur in over 50% of
human ovarian carcinomas and have been associated with shorter survival. Numerous other
proteins have been identified, which play a role in the apoptotic response, such as the
members of the BCL-2 family and the death transmembrane receptors and their ligands,
TNFc,, FasL and TRAIL.
The recent development of methodologies that allows the assessment of changes in global
gene expression in tumors will facilitate the high through put evaluation for clinical
significance of all cell biological factors that in vitro have been shown to be involved in
response to therapy. Application of cDNA microarrays allows simultaneous determination of
expression levels of thousands of mRNAs of tissue samples or cell lines and comparison of
global gene expression pattems in drug resistance and sensitivity in primary tumor cell
populations, thereby generating multiple clues to which (unknown) gene(clusters)s are
involved in drug response. At the end of chapter I several novel therapeutic strategies, based
on cell biologic aberrations that are specifrc in certain malignancies, such as the use of agents
aimed at restoration of the apoptotic machinery of the cell, are discussed.
Intraperitoneal administration of cytotoxic drugs is one of the more "classic" treatment
modifications, aimed to establish very high local drug concentrations. In chapter 2, we
describe our experience with the laparoscopic placement of peritoneal access ports, compared
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to the experience with placement by laparotomy. All patients were enrolled in a study to
receive intraperitoneal paclitaxel in combination with intravenous carboplatin and
cyclophosphamide as first- or second-line chernotherapy for ovarian carcinoma stage III/IV.
The patients had a peritoneal access port (PAP-catheter) placed subcutaneously at primary
laparotomy or by a separate laparoscopic procedure under general anesthesia. PAP-catheter
placement during laparotomy was possible in all 13 patients without complications. Thirteen
patients had laparoscopic catheter placement, using routine Veress needle insufflation. When
one patient experienced a bowel perforation at insertion of the umbilical trocar, due to
extensive adhesions, we decicled to continue with an open laparoscopic procedure. No other
procedure or catheter-related complications occurred. Therefore, laparoscopic assisted
placement of PAP-catheters is feasible, but should preferably be performed by an open
laparoscopic procedure in this patient population at risk for intraabdominal adhesions.
In chapter 3, the prognostic value is studied of the drug resistance associated proteins P-
glycoprotein (P-gp), Multidrug Resistance associated Protein (MRP1), canalicular
Multispecific Organic Anion Transporter (c-MOAT/MRP2) and the Lung Resistance Protein
(LRP) in ovarian carcinoma. The expression of P-gp, MRPI, MRP2 and LRP was determined
by immunohistochemistry on frozen tissue sections of 115 ovarian carcinoma patients and
related to clinicopathological factors, response to chemotherapy and progression free and
overall survival. Expression of P-gp was observed in lloÁ, MRPI in 44oÁ, MRP2 in l6Yo and
LRP in 74oÁ of the tumors. Expression of MRPI was related to MRP2 and P-gp expression,
while LRP expression was more frequently observed in patients with more favorable tumor
characteristics, such as early stage, low grade and smaller residual tumor. P-gp, MRPl, MRP2
and LRP expression were neither related to response to first line chemotherapy nor to
progression free or overall survival. In the multivariate analysis only stage and residual tumor
were independent prognostic factors for survival. Thus, assessment of P-gp, MRP1, MRP2 or
LRP does not allow prediction of response to chemotherapy or survival in ovarian carcinoma.
Heat shock protein 27 (hsp27) is one of the small heat shock proteins. The highly conserved
heat shock proteins accumulate in cells exposed to heat and a variety of other stressful stimuli.
They function mainly as molecular chaperones, allowing cells to adapt to gradual changes in
their environment and to survive in otherwise lethal conditions. In ovarian and breast
carcinoma cell lines, the expression of hsp27 has been associated with resistance to cisplatin
and doxorubicin. In addition hsp27 expression appears to facilitate cellular growth,
differentiation and motility.' Recently it has been shown that expression of heat shock
proteins correlates with increased resistance to apoptosis induced by a range of diverse
cytotoxic agents.3 In several human carcinomas hsp27 expression has also been related to
worse prognosls.
In chapter 4, the prognostic value of hsp27 expression is studied in patients with ovarian
carcinoma with respect to their response to chemotherapy and overall survival. Hsp27
expression was assessed by immunohistochemistry in 77 patients with ovarian carcinoma
stage IC-IV. All patients received cisplatin and doxorubicin-based chemotherapy and there
was a long-term follow-up. In 30 patients paired tumor samples, obtained before and after
chemotherapy, were available. Hsp27 immunostaining was positive in 860Á of patients before
and in 72Yo of patients after chemotherapy. Hsp 27 expression was not related to any
clinicopathologic factor or p53 expression. Univariate analysis showed that in stage III and IV
ovarian cancer patients younger age, no residual tumor after first laparotomy, < I liter ascites,
response to first line chemotherapy and absence of hsp27 expression were associated with
longer median progression-free survival. However, in multivariate analysis only age, ascites
and response to chemotherapy had independent prognostic value.

















































Summary, discussion and future perspectives
In chapter 5, the components of a specific apoptotic pathway are studied in ovarian tumors.
The Fas-Fas ligand (FasL) route appears to be involved in the physiology of follicular gowth
and atresia of normal ovaries.' Furthermore it has been shown that this apoptotic route is also
involved in the process of regeneration and atresia of the epithelial ovarian surface cells in the
normal menstrual cycle.o In this study, Fas and FasL levels in cyst fluids and sera of patients
with benign (n:30), borderline (n:5) and malignant (n:24) epithelial ovarian tumors were
evaluated by ELISA. The immunohistochemical expression of Fas and FasL in relation to p53
was also determined in the tumors of these patients. In serum, median Fas levels were
comparable in healthy women and patients with ovarian tumors, while serum FasL levels
were higher in healthy women. The median Fas levels were higher in malignant cyst fluids.
Epithelial Fas staining \r'as observed in 460Á of benign, 80% of borderline and 7 lYo of
malignant tumors, while FasL staining was more frequently present in malignant ovarian
epithelium. P53 immunostaining was not related to Fas or FasL expression. In conclusion,
serum Fas or FasL level measurements do not seem to be useful markers in patients with
ovarian carcinomas. Elevated Fas levels in malignant cyst fluids, suggest an increased
production of Fas by malignant cells. As both Fas and FasL are highly expressed in malignant
ovarian fumors, the Fas-FasL route appears an interesting apoptotic route to explore for
innovative cancer therapy.
Wild-type p53 has been implicate4 in the translocation process of Fas to the cell surface and
irt transactivation of the Fas gene.' The p53 gene, however, is frequently mutated in ovarial
carcinoma. In chapter 6, stable transfectants expressing the control vector (A2780lcmv), and
three vectors with p53 mutated at codon 175 (A27801mI75), codon 248 (A2180m248) or
codon 213 (A27801m273) were used to determine the effect of various p53 mutations on Fas
expression anC Fas-mediated cytotoxicity in an isogeneic background. Despite similar cellular
Fas levels, the cell lines A27801m248 and A27801m273 expressed more Fas on the cell
surface (10- and 5- fold respectively) compared to A2780/cmv and A27801m175, but none of
the cell lines was sensitive for the apoptosis-inducing anti-Fas antibody 7Cll. Fas cell-surface
levels became elevated in all cell lines following treatment with interferon-y (2 to 3-fold),
cisplatin (3 to 5-fold) or paclitaxel (1.3 fold). These elevated Fas cell surface levels resulted in
increased apoptosis following anti-Fas antibody 7C11 exposure. Especially A2780/m248,
insensitive to either 7C 1 I or interferon-y, was highly sensitive to a combination of 7C I I and
interferon-y. This sensitivity was demonstrated by an increase in PARP cleavage, in the
percentage apoptotic cells, and in percentual cell kill. In contrast, the high Fas cell surface
levels induced by cisplatin did not result in an enhanced cytotoxic effect of cisplatin in
combination with 7ClI. These results demonstrate that upregulation of Fas on the cell surface
following interferon-y treatment may be used to enhance cell kill independently of the p53
status of ovarian tumor cells. This also indicates that, despite the occurrence of a high
percentage of p53 mutations, especially the combination treatment of interferon-y and an anti-
Fas antibody might enhance the effrciency of current platinum-based chemotherapy for
patients with ovarian carcinoma. However, a significant problem that could hamper the
success of FasL as therapeutic agent, is the severe hepatotoxicity of FasL, as was encountered
in mice.
Recently, TRAIL, a member of the TNF cytokine famlly, that triggers rapid apoptosis in
various tlpes of tumor cells has drawn more attention.ó TRAIL can interact with two death
receptors, death receptor 4 and 5 (DR4 and 5) and two decoy receptors, decoy receptor I and
2 (DcRl and DcR2). In contrast to TNFo, and FasL, cytotoxicity to TRAIL appears to be
tumor selective, thereby making TRAIL a more promising new candidate for the ffeatment of
carcinomas. Until now however, little is known about the expression of TRAIL and its
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receptors in human carcinomas. Therefore, in chapter 7, the expression of the death ligand
TRAIL and its death receptors DR4 and DR5 and DcRl is studied by immunohistochemistry
in normal ovaries and in patients with early or advanced stage ovarian carcinoma. In the latter
group, tissue was available at diagnosis and at second look laparotomy, performed after three
or six cycles of chemotherapy, allowing the study of potential induction of TRAIL and its
receptors by exposure to chemotherapy.
In normal ovaries immunostaining for TRAIL, DR4 and DR5 was observed only in the
cytoplasm of ovarian surface epithelium, whereas immunostaining for DcRl also was
observed in the ovarian stromal cells. Immunostaining for TRAIL was observed in 34%, DR5
rn 5loÁ, DR4 in 7loÁ and DcR I in 44% of the primary tumors. Eighty eight percent of the
tumors was positive for at least one death receptor. All staining pattems were cytoplasmatic
and within a tumor generally weaker in undifferentiated parts of the tumor. TRAIL was more
frequently expressed in early stage tumors, compared to advanced stage tumors. No other
correlations of TRAIL, DR4, DR5 and DcRl with any clinicopathological characteristic were
found. Also no relations were observed with response to chemotherapy or survival (in this
small group of patients). DR5 was more frequently observed in residual tumors after
chemotherapy than before chemotherapy. This is in line with in vitro results in other tumor
types, where especially DR5 upregulation (and enhanced cytotoxicity to TRAIL) is observed
upon treatment of tumor cells with cytotoxic drugs. As early, advanced and relapsed tumors
all show high expression of at least DR4 or DR5, the clinical use of recombinant human
TRAIL is a potentially interesting therapeutic option to explore in ovarian carcinoma,
especially in drug resistant umors.
General discussion and future perspectives
Although 80% of patients with advanced ovarian carcinoma respond to first-line treatment,
the majority will eventually relapse. Response rates to a variety of agents shown to be
effective as second line heatment all range from 20-30Yo and will seldom be curative. The
identification of relevant prognostic factors in ovarian carcinoma, might provide targets for
novel therapeutic strategies.
Although the (multi)drug resistance related proteins P-gp, MRPI, MRP2 and LRP are
frequently expressed by ovarian tumors, we showed that their expression is not related to
resistance to chemotherapy or to survival. It could be assumed that tumors expressing all four
drug resistance associated proteins, would be poor responders to first line chemotherapy.
However, based on expression of these drug resistance related proteins, we were unable to
identify a subgroup of patients with an unfavorable response to chemotherapy. This might be
due to the co-expression of yet unidentified other proteins which act as e.g. drug-efflux
pumps. Recently several new drug-efflux pumps have been identified.' The contribution of
these new drug-efflux pumps to clinical drug resistance however, remains to be established.
Drug-efflux pumps or drug-resistance associated proteins have a physiological role in normal
tissues. Clinical studies aimed at reversal of P-glycoprotein have not provided any benefit for
patients with solid tumors. It may well be that drug resistance in the clinic is only possible if
more than one drug resistance mechanism is attacked.
It is becoming increasingly apparent that conventional chemotherapeutic drugs exert their
function ultimately via the cellular machinery that controls the cell cycle and the molecular
pathways that mediate progrcmmed cell death or apoptosis. Suppression of drug-induced
apoptosis, despite imposition of drug-induced damage, is considered to be a general
mechanism for drug resistance of tumor cells. In chapter 5 and 6 different aspects of the Fas-
FasL apoptotic route are studied to explore its potential as a possible therapeutic target. In



























Summary, discus ion and future perspectives
chapter 5, we show that the majority of ovarian carcinomas express both Fas and FasL. This
has also been observed in other studies in ovarian carcinoma. For several other frrmor types
(esophagus, colon, breast) Fas expression appeared to be downregulated in malignant tumors
compared to their benign counterparts. while FasL expression was upregulated. It has been
suggested that alterations in the expression of Fas and/or Fasl that occur during malignant
transformation might render tumor cells resistant to T-cell mediated apoptosis. Our study
shows that Fas expression is not downregulated in malignant ovarian tumors but that FasL
expression is indeed upregulated in malignant fumors compared to benign and borderline
fumors. This was confirmed in a larger study of Munakata et al.r0 In their study FasL positive
tumors had a shorter overall survival compared to FasL negative tumors. In cystic fluids of
malignant tumors, we observed an increased Fas accumulation, which may point to an
increased soluble Fas production by malignant ovarian tumor cells. This may also contribute
to a decreased sensitivity of tumor cells to T-cell mediated apoptosis. FasL was not elevated,
neither in cystic fluids nor in sera from patients with malignant tumors. The abundant Fas
expression in ovarian carcinomas supports the use of anti-Fas or rhFasl as a novel therapeutic
strategy. However there remain several problems which could seriously hamper this approach.
A lack of Fas cell surface expression will result in relative resistance to Fas-mediated
apoptosis. We used immunohistochemistry to study the Fas expression and observed
especially a cytoplasmatic staining pattern. Immunohistochemistry however, is not sensitive
enough to permit any firm conclusion about the expression of Fas on the cell membrane.
Currently no data exists on the functionality of the Fas receptor in ovarian carcinomas.
Mutations in the Fas gene have been described in other human carcinomas, although not
frequently.
Wild type p53 has been implicated in the process of Fas translocation to the cell surface and
in ffansactivation of the Fas gene, while the p53 gene is'frequently mutated in ovarian
carcinoma. In our study, described in chapter 6, we show that in stable transfectants of the
ovarian carcinoma cell line A2780, expressing either a control vector (A2780/cmv), or vectors
mutated at codon 175 (A27801m175),248 (A27801m248\ or 273 (A27801m273), treatment
with cisplatin, paclitaxel and interferon-y results in upregulation of Fas on the cell surface.
This upregulation was not restricted to wild-type p53 status. Especially in the A27801m248,
not sensitive to either 7C I 1 or interferon-y alone, combination of 7C I 1 and interferon-y
resulted in enhanced cytotoxicity, accompanied by increased PARP cleavage, increased
percentage apoptotic cells and cell kill. Other reports have demonstrated that ovarian
carcinoma cells, initially not sensitive for anti-Fas antbody, can be sensitized to anti-Fas
antibody by subtoxic concentrations of cisplatin. Although our study showed upregulation of
Fas cell surface expression upon treatment with cisplatin, mutant p53 transfected A2780 cells
were not very sensitive to anti-Fas antibody treatment following cisplatin exposure. As no
mutations in the Fas gene have been found in A2780 or in other human ovarian carcinoma
cell lines,. this suggests that probably intracellular inhibitors of Fas-mediated apoptosis are
involved. " Thus, upregulation of Fas on the cell surface following treatment with cisplatin or
interferon-y may be used to enhance cell kill independently of the p53 status of ovarian
carcinoma cells. However, the existence of different intracellular mechanisms for apoptosis
inhibition could present a major problem. Therefore future studies should focus on obtaining
more insight into these mechanisms. In this respect, the use of short term cultures of human
ovarian carcinoma cells is an interesting model to study the functionality of the Fas/FasL
pathway.
Despite the above described obstacles, which theoretically could hamper the success of
anticancer treatment with anti-Fas or recombinant F'asL, experiments in mice have shown that
both anti-Fas antibodies and recombinant FasL are capable to induce tumor regression.
Unfortunately systemic delivery of these agents also caused severe damage to the liver of the
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mice. There are however, several poteniial options to avoid or reduce this liver toxicity, such
as local intra-tumor administration of anti-Fas or recombinant FasL, gene therapy, or the use
of a caspas.,e-9 inhibitor, which may protect liver cells from death receptor-mediated
apoptosls. '-
Although the induction of F'as-mediated apoptosis as anticancer treatment remains an
interesting option to explore further, the use of another apoptosis inducting ligand, TRAIL,
might be more promising, mainly due to its tumor selectivity. In our immunohistochemical
study, we observed frequent expression of the death receptors DR4 and 5 in ovarian
carcinomas. Interestingly, expression of DR5 was even more frequent in tumor samples
obtained after chemotherapy compared to primary tumor samples. This corresponds with in
vitro results which also show predominantly upregulation of DR5 upon exposure of tumor cell
lines to chemotherapy. This increase is in vitro accompanied by an increased sensitivity to
TRAIL. It is tempting to speculate that the observed increased expression of DR5 in our
study, also points to a potential increase in cytotoxicity of chemotherapy if combined with
TRAIL. We observed a lower TRAIL expression in advanced stage ovarian carcinomas
compared to early stage carcinomas. If confirmed in a larger series, this depletion of TRAIL
in advanced stage carcinomas would provide an even further support for the administration of
TRAIL as antitumor therapy in advanced ovarian carcinoma.
In conclusion, although in the last decades our knowledge of the cellular events that play a
role in resistance to chemotherapy has increased tremendously, this has not yet resulted in a
treatment advantage for patients with advanced ovarian carcinoma. So far, most studies
evaluated only one or two separate cell biological parameters, while it is obvious that clinical
drug resistance is multifactorial and far more complex than previously assumed. Recent
advances in methodology for simultaneous analysis of differential gene expression pattems
allow for the determination of expression levels of thousands of different mRNAs of tissue
samples. The use of oDNA micro-arrays for the comparison of global gene expression
patterns in drug resistant and sensitive primary fumor cell populations will identify many
more potential molecular markers that contribute to the response of a tumor to chemotherapy.
This should result in stratification, aimed at targetting several different molecular markers
simultaneously and reveal the right target in the right patient.
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